Pharma Mar ( Grupo Zeltia ) esta buscando a un máximo responsable de Comunicación .

Pedro Luis González, hasta la fecha Director de Comunicación de Pharma Mar (Grupo Zeltia) ha abandonado su cargo hace escasos días. Con su salida, la compañía presidida por José María Fernández Sousa-Faro ha comenzado un proceso de selección para incorporar a un profesional que conozca el sector y sea capaz de articular un equipo que dé servicio tanto a su filial como a la multinacional cotizada .

Yondelis Fase II Pediatrica en la Pediatric Central IRB Meeting Agenda a celebrar el 14 Febrero del 2008 .

CIRB Approved Protocols

COG-ADVL0221
Lead Group:
COG
"A Phase II Study of ET-743 in Children with Recurrent Sarcomas"
2/24/2005 1/28/2008 1/20/2009

http://www.cancer.gov/clinicaltrials/COG-ADVL0221

Expected Enrollment
60
A total of 30-60 patients (10-20 per stratum) will be accrued for this study within 2 years.

Outline

This is a multicenter study. Patients are stratified according to disease (Ewing's sarcoma family of tumors vs rhabdomyosarcoma vs nonrhabdomyosarcomatous soft tissue sarcoma).

Patients receive ecteinascidin 743 IV over 3 hours on day 1. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed at 30 days.

Trial Contact Information

Trial Lead Organizations

Children's Oncology Group

Sylvain Baruchel, MD, Protocol chair Ph: 416-813-7795


Trial Sites

U.S.A.

Kentucky

Lexington

Lucille P. Markey Cancer Center at University of Kentucky

Clinical Trials Office - Markey Cancer Center at University of Kentucky Chandler Medical Center Ph: 859-257-3379


Registry Information

Official Title A Phase II Study Of Trabectedin (ET-743, Yondelis®) in Children With Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Nonrhabdomyosarcomatous Soft Tissue Sarcoma

Trial Start Date 2008-01-28

Registered in ClinicalTrials.gov NCT00070109

Date Submitted to PDQ 2003-08-14

Information Last Verified 2008-02-01

NCI Grant/Contract Number CA98543